Wayne Dimech examines the quality - or lack thereof - of SARS-Cov-2 testing. Wayne Dimech is Executive Manager, Scientific and Business Relations at NRL, Australia (NRL) in Melbourne. He is a recognized expert in infectious disease serology and laboratory quality.
A few months into the Covid19 crisis, we need to stop treating it as a short-term crisis and start preparing it like it's a long-term emergency.
It's October 2020. Time to take a hard look at truth, untruth, and the consequences of pretending there's no difference.
It's 2021, the new year, so of course it's time for someone to suggest a new way to do QC. This time it's the metrologists, and their proposal has a few merits and many more downsides.
Continuing in our series of Sigma analysis of the leading diagnostic platforms, we turn our attention to the Abbott Alinity, and assess what goals can be achieved by this chemistry instrument.
We know how to change QC frequency in a data-driven, evidence-based, patient-risk focused way. But we don't seem to be doing it at all.
Taking some recent cobas 8000 data, we assess what goals can be achieved by one of the leading chemistry platforms.